-
7m 4sPart 2 | Session 2 Activity of EPA on Lp(a) Oxidation
In this video, Prof Philippe Gabriel Steg provides an overview on the abstract from ACC 2026, 'Efficacy of Icosapent Ethyl Among Patients at Extreme Cardiovascular Risk: A Secondary Analysis of REDUCE-IT'.
Filmed at ACC 2026, these expert-led videos presented by Prof Philippe Gabriel Steg (Hôpital Bichat, Paris, FR) and Dr Samuel Sherratt (Elucida Research & Mount Sinai Fuster Heart Hospital, US) provide a focused overview of contemporary lipid management and cardiovascular risk reduction. They examine residual cardiovascular risk beyond triglycerides, alongside evolving evidence on eicosapentaenoic acid (EPA), including insights from REDUCE-IT and emerging mechanistic data.
Together, the sessions highlight how guideline updates and new evidence can be translated into practical, real-world care.
Learning Objectives
- To summarise the latest recommendations from the ACC/AHA on the use of EPA and fibrates for CV risk reduction in high- and very high-risk patients
- To translate new recommendations with those made on previous European and diabetes guidelines into your daily practice
- To describe how EPA may achieve its clinical benefit outside of TG-lowering
- To list key patient sub-populations who may benefit from EPA
Target Audience
- Cardiologists
- Cardiovascular Specialists
- Endocrinologists
- Internal Medicine
- Lipidologists
More from this programme
Part 1
Managing CV Risk Beyond Triglycerides: Consolidating the Guidelines
This summary consolidates the ACC/AHA, ESC and ADA recommendations on EPA and fibrates for managing cardiovascular risk beyond triglycerides. Prof Philippe Gabriel Steg reviews the underpinning clinical data and guideline differences into practical decision-making.
Part 2
Emerging Insights on the Role of EPA
Faculty Biographies
Philippe Gabriel Steg
Interventional Cardiologist
Prof Philippe Gabriel Steg works as an Interventional Cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, in Paris, France.
Prof Steg’s research interests are in the field of coronary artery disease. He is a former member of the Board of the French Society of Cardiology, an honorary member of the Institut Universitaire de France, and received the silver medal of the European Society of Cardiology in 2011.
Prof Steg led the TAO and EUROMAX trials and is chairing or co-chairing several trials or registries, such as ODYSSEY-CV Outcomes, CLARIFY, THEMIS. Prof Steg has authored more than 650 articles in peer-reviewed international journals. He is a member of the editorial boards for Circulation, Circulation: Cardiovascular Interventions, the European Heart Journal, and the European Heart Journal – Cardiovascular Pharmacotherapy. He is deputy editor for the…